A single positive laboratory test among those exploring the presence of antiphospholipid antibodies is not associated with thromboembolic events and does not identify patients with antiphospholipid syndrome. On the other hand, more than one laboratory test positive, and in particular all three tests positive, is strongly associated to thromboembolic events and identifies high risk patients. Triple positivity is in fact related to the presence of a specific anti-b2-glycoprotein I (anti-Domain I) antibody, also able to prolong coagulation tests. Monoclonal antibodies against Domain I with Lupus Anticoagulant activity might be candidate material for standardization of antiphospholipid assays. Much work remains to be done in this field. Lupus (2012) 21, 732-733.
Laboratory tests for the diagnosis of antiphospholipid syndrome (APS) comprise one coagulation test (Lupus Anticoagulant, LA) and two enzyme-linked immunosorbent assays (ELISAs) to detect anticardiolipin (aCL) and anti-b2-glycoprotein I (ab2GPI) antibodies. 1 Tests for LA and aCL are non-specific as they do not identify specific antibodies. In contrast, the ELISA for ab2GPI detects autoantibodies specifically directed to human b2GPI. Although specific, the ab2GPI ELISA does not distinguish between autoantibodies directed to the various domains (I-II-III-IV-V) of the protein. It is now clear that only some autoantibodies, those directed to Domain I (DmI) of the molecule, are associated with thromboembolic events. 2 Thus, limiting aPL testing to autoantibodies to b2GPI may not specifically identify the relevant autoantibodies and the sole positivity in the ab2GPI ELISA may not be associated, as in our experience, 3 with thromboembolic events.
In the absence of a specific ELISA to detect anti-DmI antibodies, how can we identify this subset of autoantibodies? As anti-DmI antibodies possess LA activity, 4 this could be easily done by demonstrating the concomitant presence of LA in the original plasma. Therefore positivity in ab2GPI ELISA and the presence of LA would help identify the pathogenic ab2GPI antibodies. In addition, as the standardization of the ELISA for ab2GPI antibodies is poor, 5 a positive aCL ELISA reinforces the potential to identify the pathogenic antiphospholipid (aPL).
Positivity in all three tests (triple positivity) is frequent in APS patients at high risk of a new thromboembolic event 6 as well as in carriers at risk of developing a first thromboembolic event. 7 To further confirm the hypothesis that triple positivity reveals the presence of pathogenic antibodies, we demonstrated that affinity purified IgG ab2GPI from plasma of patients with triple positivity spiked with normal plasma reproduces the positivity of all three tests found in the original plasma. 8 The presence of antibodies to DmI in triple positive APS patients has recently been shown by our group by means of a competitive ELISA using synthetic DmI. 9 In conclusion, triple positivity resemble patients with a true autoimmune disease as the main autoantibody (ab2GPI) is identified, the corresponding target antigen is known and an analogous response (antibodies against injected b2GPI) causes a similar disease in experimental animals. 10 At variance with this well defined laboratory picture (classification category I in the Sydney consensus statement), 1 a single positive test (classification category II) is not associated with thromboembolic events (Table 1 3 ,6,11,12 ) .
A subgroup in classification category I (more than one positive test) with both aCL and ab2GPI antibody positivity but negative for LA (other combinations are uncommon) has modest association with thrombosis and low recurrence rate for thrombosis and pregnancy morbidity in the follow-up period. 3, 11 Thus, the laboratory profile of patients with suspected APS is essential and should be carefully considered when deciding the type and duration of the antithrombotic treatment.
As far as the standardization of laboratory tests for the diagnosis of APS is concerned, there is a tremendous need for reference material. Monoclonal antibodies to DmI with LA activity might be a solution. In the meantime, the establishment of a reference laboratory should be considered for multicentre studies to enrol a homogenous population of patients with APS. In our experience, 24% (71/302) of samples tested in our lab for the confirmation of the presence of LA were found to be negative. 13 Moreover, a survey of the performance of clinical laboratories in performing aPL ELISAs assessed by using lyophilized affinity-purified IgG with aCL and ab2GPI activity showed alarming results. 5 A wide variability in the results pertaining to the positive samples was found for the aCL as well as for the ab2GPI ELISAs (coefficient of variation of more than 50%). 5 This was confirmed when the analysis was restricted to those centres using the same commercial kit. Thus, much work remains to be done in this field.
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